Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer
Open accessAbstract
Significance: Small-cell lung cancer (SCLC) is an aggressive carcinoma with few effective treatment options beyond first-line chemotherapy. BH3 mimetics, such as ABT-263, promote apoptosis in SCLC cell lines, but early phase clinical trials demonstrated no significant clinical benefit. Here, we examine the sensitivity of a large panel of cancer cell lines, including SCLC, to ABT-263 and find that high Bcl2-interacting mediator of cell death (BIM) and low myeloid cell leukemia 1 (MCL-1) expression together predict sensitivity. SCLC cells relatively resistant to ABT-263 are sensitized by TORC1/2 inhibition via MCL-1 reduction. Combination of ABT-263 and TORC1/2 inhibition stabilizes or shrinks tumors in xenograft models, in autochthonous SCLC tumors in a genetically engineered mouse model, and in a patient-derived xenograft SCLC model. Collectively, these data support a compelling new therapeutic strategy for treating SCLC.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There is a growing body of evidence suggesting that deficient apoptosis induction following targeted therapy treatments can lead to a lack of efficacy.
“There is a growing body of evidence suggesting that deficient apoptosis induction following targeted therapy treatments can lead to a lack of efficacy”
From Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in <i>KRASG12C</i> -mutant Colorectal Cancer (2023) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · see citing works
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · see citing works
Self-citationABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992 · see citing works
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Peifer, M., Fernandez‐Cuesta, L., Sos, M. L., George, J., Seidel, D., Kasper, L. H., Plenker, D., Leenders, F., Sun, R., Zander, T., et al. (2012) · Nature Genetics · doi:10.1038/ng.2396 · Cited by 1,390 · see citing works
van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,237 · see citing works
Rudin, C. M., Durinck, S., Stawiski, E. W., Poirier, J. T., Modrusan, Z. D., Shames, D. S., Bergbower, E. A. S., Guan, Y., Shin, J., Guillory, J., et al. (2012) · Nature Genetics · doi:10.1038/ng.2405 · Cited by 1,066 · see citing works
Programmed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031 · cited 1× · see citing works
“ABT-263 was well tolerated in the clinic with a dose-limiting toxicity of thrombocytopenia (22), an on-target toxicity of BCL-XL inhibition (23).”
BackgroundRoberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S., Huang, D. C. S., Xiong, H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 833 · see citing works
Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 813 · see citing works
Chresta, C. M., Davies, B. R., Hickson, I., Harding, T. C., Cosulich, S. C., Critchlow, S. E., Vincent, J. P., Ellston, R. P. A., Jones, D., Sini, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 796 · see citing works
Hanna, N. H., Bunn, P. A., Langer, C. J., Einhorn, L. H., Guthrie, T. H., Beck, T., Ansari, R., Ellis, P., Byrne, M., Morrison, M. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8595 · Cited by 677 · see citing works
Nguyen, M., Marcellus, R. C., Roulston, A., Watson, M., Serfass, L., Madiraju, S. R. M., Goulet, D., Viallet, J., Bélec, L., Billot, X., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709443104 · Cited by 658 · see citing works
Meuwissen, R., Linn, S. C., Linnoila, R. I., Zevenhoven, J., Mooi, W. J., & Berns, A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00220-4 · Cited by 643 · see citing works
Moore, V. D. G., Brown, J. R., Certo, M. V., Love, T. M., Novina, C. D., & Letai, A. G. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28281 · Cited by 604 · see citing works
Gandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6208 · Cited by 603 · see citing works
Rossi, A., Maïo, M. D., Chiodini, P., Rudd, R., Okamoto, H., Skarlos, D. V., Früh, M., Qian, W., Tamura, T., Samantas, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.4905 · Cited by 570 · see citing works
Rudin, C. M., Hann, C. L., Garon, E. B., de Oliveira, M. R., Bonomi, P., Camidge, D. R., Chu, Q. S.-C., Giaccone, G., Khaira, D. K., Ramalingam, S. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3090 · Cited by 563 · see citing works
Sutherland, K. D., Proost, N., Brouns, I., Adriaensen, D., Song, J.-Y., & Berns, A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.019 · Cited by 534 · see citing works
Dissecting eIF4E action in tumorigenesis.Preprint
Wendel, H., Silva, R. L. A., Malina, A., Mills, J., Zhu, H., Ueda, T., Watanabe‐Fukunaga, R., Fukunaga, R., Teruya-Feldstein, J., Pelletier, J., et al. (2007) · Genes & Development · doi:10.1101/gad.1604407 · Cited by 512 · see citing works
Hsieh, A. C., Costa, M. D., Zollo, O., Davis, C. B., Feldman, M. E., Testa, J. R., Meyuhas, O., Shokat, K. M., & Ruggero, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.021 · Cited by 464 · see citing works
Chen, S., Dai, Y., Harada, H., Dent, P., & Grant, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3964 · Cited by 385 · see citing works
Self-citationDifferential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
Faber, A. C., Li, D., Song, Y., Liang, M., Yeap, B. Y., Bronson, R. T., Lifshits, E., Zhao, C., Maira, S.-M., Garcı́a-Echeverrı́a, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905056106 · Cited by 315 · see citing works
Self-citationGenetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing
McFadden, D. G., Papagiannakopoulos, T. Y., Taylor-Weiner, A. N., Stewart, C., Carter, S. L., Cibulskis, K., Bhutkar, A. J., McKenna, A., Dooley, A. L., Vernon, A. N., et al. (2014) · Cell · doi:10.1016/j.cell.2014.02.031 · Cited by 289 · see citing works
Self-citationmTORC1 promotes survival through translational control of Mcl-1
Mills, J. R., Hippo, Y., Robert, F., Chen, S. M. H., Malina, A., Lin, C.-J., Trojahn, U., Wendel, H.-G., Charest, A., Bronson, R. T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804821105 · Cited by 285 · see citing works
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
Faber, A. C., Corcoran, R. B., Ebi, H., Sequist, L. V., Waltman, B. A., Chung, E., Incio, J., Digumarthy, S. R., Pollack, S. F., Song, Y., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0106 · Cited by 283 · see citing works
Self-citationLin, X., Morgan-Lappe, S. E., Huang, X., Li, L., Zakula, D., Vernetti, L. A., Fesik, S. W., & Shen, Y. (2006) · Oncogene · doi:10.1038/sj.onc.1210166 · Cited by 245 · see citing works
Costa, C., Molina, M. A., Drozdowskyj, A., Giménez-Capitán, A., Bertran-Alamillo, J., Karachaliou, N., Gervais, R., Massuti, B., Wei, J., Moran, T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2233 · Cited by 229 · see citing works
Self-citationTherapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer
Hann, C. L., Daniel, V. C., Sugar, E. A., Dobromilskaya, I., Murphy, S. C., Cope, L., Lin, X., Hierman, J. S., Wilburn, D. L., Watkins, D. N., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5031 · Cited by 213 · see citing works
Sartorius, U., & Krammer, P. H. (2001) · International Journal of Cancer · doi:10.1002/ijc.10096 · Cited by 206 · see citing works
Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
Shoemaker, A. R., Mitten, M. J., Adickes, J., Ackler, S., Refici, M. L., Ferguson, D. C., Oleksijew, A., O'Connor, J. M., Wang, B., Frost, D. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4622 · Cited by 203 · see citing works
Nuclear factor I/B is an oncogene in small cell lung cancerPreprint
Dooley, A. L., Winslow, M. M., Chiang, D. Y., Banerji, S. O., Stransky, N., Dayton, T. L., Snyder, E. L., Senna, S., Whittaker, C. A., Bronson, R. T., et al. (2011) · Genes & Development · doi:10.1101/gad.2046711 · Cited by 172 · see citing works
Self-citationIn vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
Mason, K. D., Vandenberg, C. J., Scott, C. L., Wei, A. H., Cory, S., Huang, D. C. S., & Roberts, A. W. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809957105 · Cited by 136 · see citing works
Faber, A. C., Coffee, E. M., Costa, C., Dastur, A., Ebi, H., Hata, A. N., Yeo, A. T., Edelman, E. J., Song, Y., Tam, A. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0315 · Cited by 124 · see citing works
Self-citationSchatz, J. H., Oricchio, E., Wolfe, A. L., Jiang, M., Linkov, I., Maragulia, J. C., Shi, W., Zhang, Z., Rajasekhar, V. K., Pagano, N. C., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20110846 · Cited by 116 · see citing works
Hwang, J. J., Kuruvilla, J. G., Mendelson, D. S., Pishvaian, M. J., Deeken, J. F., Siu, L. L., Berger, M. S., Viallet, J., & Marshall, J. L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0822 · Cited by 106 · see citing works
Small Cell Lung Cancer: Past, Present, and Future
Rodríguez, E., & Lilenbaum, R. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0120-5 · Cited by 100 · see citing works
Paik, P. K., Rudin, C. M., Pietanza, M. C., Brown, A. B., Rizvi, N. A., Takebe, N., Travis, W. D., James, L. P., Ginsberg, M. S., Juergens, R. A., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.05.005 · Cited by 98 · see citing works
Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK
McCoy, F. P. G., Hurwitz, J. L., McTavish, N., Paul, I., Barnes, C., O’Hagan, B. M. G., Odrzywół, K. E., Murray, J. T., Longley, D. B., McKerr, G., et al. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.86 · Cited by 90 · see citing works
Al-harbi, S., Hill, B. T., Mazumder, S., Singh, K., DeVecchio, J., Choudhary, G. S., Rybicki, L. A., Kalaycio, M. E., Maciejewski, J. P., Houghton, J. A., et al. (2011) · Blood · doi:10.1182/blood-2011-03-340364 · Cited by 85 · see citing works
Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation
Cope, C. L., Gilley, R., Balmanno, K., Sale, M. J., Howarth, K., Hampson, M., Smith, P. D., Guichard, S. M., & Cook, S. J. (2013) · Journal of Cell Science · doi:10.1242/jcs.137588 · Cited by 79 · see citing works
Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
Singh, M., Couto, S. S., Forrest, W. F., Lima, A., Cheng, J. H., Molina, R., Long, J. E., Hamilton, P., McNutt, A., Kasman, I. M., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4053 · Cited by 72 · see citing works
Apoptosis In Targeted Therapy Responses
Faber, A. C., Ebi, H., Costa, C., & Engelman, J. A. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00016-6 · Cited by 62 · see citing works
Self-citationSale, M. J., & Cook, S. J. (2013) · Biochemical Journal · doi:10.1042/bj20121212 · Cited by 58 · see citing works
Rapamycin Rescues ABT-737 Efficacy in Small Cell Lung Cancer
Gardner, E. E., Connis, N., Poirier, J. T., Cope, L., Dobromilskaya, I., Gallia, G. L., Rudin, C. M., & Hann, C. L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3460 · Cited by 54 · see citing works
Subversion of the Bcl-2 Life/Death Switch in Cancer Development and TherapyPreprint
Adams, J. M., Huang, D. C. S., Strasser, A., Willis, S. N., Chen, L., Wei, A. H., van Delft, M. F., Fletcher, J. I., Puthalakath, H., Kuroda, J., et al. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.009 · Cited by 33 · see citing works
Flagged first, then by citations
1 of the 46 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Rudin, C. M., Brambilla, E. M., Finn, C. F., & Sage, J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00235-0 · Cited by 1,632 · see citing works
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619 · see citing works
Self-citationPathways and mechanisms of venetoclax resistance
Bose, P., Gandhi, V. V., & Konopleva, M. Y. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1283032 · Cited by 302 · see citing works
Origins, genetic landscape, and emerging therapies of small cell lung cancerPreprint
Semenova, E. A., Nagel, R., & Berns, A. J. M. (2015) · Genes & Development · doi:10.1101/gad.263145.115 · Cited by 247 · see citing works
Regulation of Bim in Health and Disease
Sionov, R. V., Vlahopoulos, S., & Granot, Z. (2015) · Oncotarget · doi:10.18632/oncotarget.5492 · Cited by 225 · see citing works
Senescent alveolar macrophages promote early-stage lung tumorigenesis
Prieto, L. I., Sturmlechner, I., Graves, S. I., Zhang, C., Goplen, N. P., Yi, E. S., Sun, J., Li, H., & Baker, D. J. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.006 · Cited by 212 · see citing works
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
Drapkin, B. J., George, J., Christensen, C. L., Mino-Kenudson, M. A., Dries, R., Sundaresan, T. K., Phat, S., Myers, D. T., Zhong, J., Igo, P., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0935 · Cited by 211 · see citing works
Self-citationHDAC inhibitors elicit metabolic reprogramming by targeting super-enhancers in glioblastoma models
Nguyen, T. T. T., Zhang, Y., Shang, E., Shu, C., Torrini, C., Zhao, J., Bianchetti, E., Mela, A., Humala, N., Mahajan, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129049 · Cited by 201 · see citing works
Bunn, P. A., Minna, J. D., Augustyn, A., Gazdar, A. F., Ouadah, Y., Krasnow, M. A., Berns, A. J. M., Brambilla, E. M., Rekhtman, N., Massion, P. P., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.012 · Cited by 180 · see citing works
Self-citationTargeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
Inoue‐Yamauchi, A., Jeng, P., Kim, K., Chen, H., Han, S., Ganesan, Y. T., Ishizawa, K., Jebiwott, S., Dong, Y., Pietanza, M. C., et al. (2017) · Nature Communications · doi:10.1038/ncomms16078 · Cited by 176 · see citing works
Simpson, K., Stoney, R., Frese, K. K., Simms, N., Rowe, W., Pearce, S. P., Humphrey, S., Booth, L., Morgan, D., Dynowski, M., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0046-2 · Cited by 173 · see citing works
D’Aguanno, S., & Bufalo, D. D. (2020) · Cells · doi:10.3390/cells9051287 · Cited by 152 · see citing works
Identification of DHODH as a therapeutic target in small cell lung cancer
Li, L., Ng, S. R., Colón, C. I., Drapkin, B. J., Hsu, P. P., Li, Z., Nabel, C. S., Lewis, C. A., Romero, R., Mercer, K. L., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw7852 · Cited by 141 · see citing works
Self-citationVenetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression
Lochmann, T. L., Floros, K. V., Naseri, M., Powell, K. M., Cook, W., March, R. J., Stein, G. T., Greninger, P., Maves, Y. K., Saunders, L. R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1606 · Cited by 134 · see citing works
Self-citationShahbandi, A., Rao, S. G., Anderson, A. Y., Frey, W. D., Olayiwola, J. O., Ungerleider, N., & Jackson, J. G. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0564-6 · Cited by 131 · see citing works
Ham, J., Costa, C., Sano, R., Lochmann, T. L., Sennott, E. M., Patel, N. U., Dastur, A., Gomez‐Caraballo, M., Krytska, K., Hata, A. N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.01.002 · Cited by 130 · see citing works
Self-citationLeverson, J. D., Sampath, D., Souers, A. J., Rosenberg, S. H., Fairbrother, W. J., Amiot, M., Konopleva, M. Y., & Letai, A. G. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0797 · Cited by 126 · see citing works
How to Use a Chemotherapeutic Agent When Resistance to It Threatens the Patient
Hansen, E., Woods, R. J., & Read, A. F. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2001110 · Cited by 118 · see citing works
Soderquist, R. S., Crawford, L. A., Liu, E., Lu, M., Agarwal, A., Anderson, G. R., Lin, K., Winter, P. S., Çakır, M., & Wood, K. C. (2018) · Nature Communications · doi:10.1038/s41467-018-05815-z · Cited by 122 · see citing works
Signal pathways and precision therapy of small-cell lung cancer
Yuan, M., Zhao, Y., Arkenau, H., Lao, T., Chu, L., & Xu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01013-y · Cited by 118 · see citing works
Wang, M., Han, J., Marcar, L., Black, J. C., Liu, Q., Li, X., Nagulapalli, K., Sequist, L. V. D., Mak, R. H., Benes, C. H., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0808 · Cited by 108 · see citing works
Self-citationSmall cell lung cancer: Novel treatments beyond immunotherapy
Meijer, J.-J., Leonetti, A., Airò, G., Tiseo, M., Rolfo, C. D., Giovannetti, E., & Vahabi, M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.004 · Cited by 107 · see citing works
BCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis
Gibson, C. J., & Davids, M. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0364 · Cited by 97 · see citing works
Cellular and molecular biology of small cell lung cancer: an overview.
Karachaliou, N., Pilotto, S., Lazzari, C., Bria, E., de Marinis, F., & Rosell, R. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2016.01.02 · Cited by 96 · see citing works
Kim, D. W., Wu, N., Kim, Y., Cheng, P. F., Basom, R., Kim, D., Dunn, C. T., Lee, A. Y., Kim, K., Lee, C. S., et al. (2016) · Genes & Development · doi:10.1101/gad.279307.116 · Cited by 96 · see citing works
Song, K.-A., Niederst, M. J., Lochmann, T. L., Hata, A. N., Kitai, H., Ham, J., Floros, K. V., Hicks, M. A., Hu, H., Mulvey, H. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1577 · Cited by 95 · see citing works
Self-citationBH3-only protein BIM: An emerging target in chemotherapy
Shukla, S., Saxena, S., Singh, B. K., & Kakkar, P. (2017) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2017.09.002 · Cited by 87 · see citing works
Dammert, M. A., Brägelmann, J., Olsen, R. R., Böhm, S., Monhasery, N., Whitney, C. P., Chalishazar, M. D., Tumbrink, H. L., Guthrie, M. R., Klein, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11371-x · Cited by 82 · see citing works
Arai, S., Jonas, O. H., Whitman, M. A., Corey, E., Balk, S. P., & Chen, S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0549 · Cited by 71 · see citing works
Dorantes-Heredia, R., Ruiz-Morales, J. M., & Cano-García, F. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.07.10 · Cited by 71 · see citing works
Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216
Thummuri, D., Khan, S. U., Underwood, P. W., Zhang, P., Wiegand, J. S., Zhang, X., Budamagunta, V., Sobh, A., Tagmount, A., Loguinov, A., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0474 · Cited by 71 · see citing works
Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG
Balakrishnan, I., Danis, E. P., Pierce, A. M., Madhavan, K. P. C., Wang, D., Dahl, N. A., Sanford, B. L., Birks, D. K., Davidson, N., Metselaar, D. S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108286 · Cited by 67 · see citing works
Mahoney, C. E., Pirman, D. A., Chubukov, V., Sleger, T., Hayes, S., Fan, Z. P., Allen, E. L., Chen, Y., Huang, L., Liu, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07959-4 · Cited by 69 · see citing works
Yan, X., Li, P., Zhan, Y., Qi, M., Liu, J., An, Z., Yang, W., Xiao, H., Wu, H., Qi, Y., et al. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.01.031 · Cited by 65 · see citing works
Song, K.-A., Hosono, Y., Turner, C., Jacob, S., Lochmann, T. L., Murakami, Y., Patel, N. U., Ham, J., Hu, B., Powell, K. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0304 · Cited by 66 · see citing works
Self-citationKarachaliou, N., Codony‐Servat, J., Teixidó, C., Pilotto, S., Drozdowskyj, A., Codony, C., Giménez-Capitán, A. A., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Gervais, R., et al. (2015) · Scientific Reports · doi:10.1038/srep17499 · Cited by 64 · see citing works
To Prime, or Not to Prime: That Is the QuestionPreprint
Potter, D. S., & Letai, A. G. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030841 · Cited by 61 · see citing works
Arai, S., Varkaris, A. S., Nouri, M., Chen, S., Xie, L., & Balk, S. P. (2020) · eLife · doi:10.7554/elife.54954 · Cited by 67 · see citing works
Anderson, G. R., Wardell, S. E., Cakir, M., Crawford, L., Leeds, J. C., Nussbaum, D. P., Shankar, P. S., Soderquist, R. S., Stein, E. M., Tingley, J. P., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aae0348 · Cited by 53 · see citing works
Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade
Williams, M. M., Lee, L., Hicks, D. J., Joly, M. M., Elion, D. L., Rahman, B., McKernan, C., Sanchez, V. M., Balko, J. M., Stricker, T. P., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0280-t · Cited by 53 · see citing works
Novel therapies in small cell lung cancer.
Mamdani, H. M., Induru, R. R., & Jalal, S. I. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.07.20 · Cited by 52 · see citing works
Novel Therapies for Small Cell Lung Cancer
Koczywas, M., & Amanam, I. U. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_8 · Cited by 51 · see citing works
Activation of LXRβ inhibits tumor respiration and is synthetically lethal with Bcl‐xL inhibition
Nguyen, T. T. T., Ishida, C. T., Shang, E., Shu, C., Torrini, C., Zhang, Y., Bianchetti, E., Sanchez‐Quintero, M. J., Kleiner, G., Quinzii, C. M., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910769 · Cited by 50 · see citing works
Bcl‐2/Bcl‐xl inhibitor APG‐1252‐M1 is a promising therapeutic strategy for gastric carcinoma
Yi, H., Qiu, M., Yuan, L., Luo, Q., Pan, W., Zhou, S., Zhang, L., Yan, X., & Yang, D. (2020) · Cancer Medicine · doi:10.1002/cam4.3090 · Cited by 50 · see citing works
Yu, X., Li, W., Xia, Z., Xie, L., Ma, X., Liang, Q., Liu, L., Wang, J., Zhou, X., Yang, Y., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3442-y · Cited by 50 · see citing works
Targeting intrinsic apoptosis and other forms of cell death by BH3-mimetics in glioblastoma
Karpel‐Massler, G., Ishida, C. T., Zhang, Y., Halatsch, M., Westhoff, M., & Siegelin, M. D. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1356286 · Cited by 49 · see citing works
Pétigny-Lechartier, C., Duboc, C., Jebahi, A., Louis, M.-H., Abeilard, E., Denoyelle, C., Gauduchon, P., Poulain, L., & Villedieu, M. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0342 · Cited by 48 · see citing works
Khan, S. U., Kellish, P. C., Connis, N., Thummuri, D., Wiegand, J. S., Zhang, P., Zhang, X., Budamagunta, V., Hua, N., Yang, Y., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-022-01296-8 · Cited by 45 · see citing works
FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies
Weeden, C. E., Solomon, B., & Asselin-Labat, M.-L. (2015) · Cell Death Discovery · doi:10.1038/cddiscovery.2015.49 · Cited by 44 · see citing works
Huang, T., Ding, X., Xu, G., Chen, G., Cao, Y. Q., Peng, C., Shen, S., Lv, Y., Wang, L., & Zou, X. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1831-7 · Cited by 43 · see citing works
Targeted Therapy and Immune Therapy for Small Cell Lung Cancer
Gadgeel, S. M. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0568-3 · Cited by 42 · see citing works
Targeting anti-apoptotic pathways eliminates senescent melanocytes and leads to nevi regression
Kohli, J. S., Chen, G., Fitsiou, E., Doepner, M., Brandenburg, S. M., Faller, W. J., Ridky, T. W., & Demaria, M. (2022) · Nature Communications · doi:10.1038/s41467-022-35657-9 · Cited by 44 · see citing works
JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer
Wang, H., Hong, B., Li, X., Deng, K., Li, H., Lui, V. W. Y., & Lin, W. (2017) · Oncotarget · doi:10.18632/oncotarget.21146 · Cited by 42 · see citing works
Li, H., Liu, L., Chang, H., Zou, Z., & Xing, D. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0169-2 · Cited by 41 · see citing works
Targeted drugs in small-cell lung cancer.
Santarpía, M., Daffinà, M. G., Karachaliou, N., González‐Cao, M., Lazzari, C., Altavilla, G., & Rosell, R. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2016.01.12 · Cited by 41 · see citing works
Lallo, A., Gulati, S., Schenk, M. W., Khandelwal, G., Berglund, U. W., Pateras, I. S., Chester, C., Pham, T. M., Kalderén, C., Frese, K. K., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14542 · Cited by 40 · see citing works
Gebru, M. T., Atkinson, J. M., Young, M. M., Zhang, L., Tang, Z., Liu, Z., Lu, P., Dower, C. M., Chen, L., Annageldiyev, C., et al. (2020) · Blood · doi:10.1182/blood.2019003124 · Cited by 40 · see citing works
Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Zhang, S., Chen, Y., Tian, C., He, Y., Tian, Z., Wan, Y., & Liu, T. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200610174453 · Cited by 37 · see citing works
Khan, S. U., Cao, L. S., Wiegand, J. S., Zhang, P., Zajac‐Kaye, M., Kaye, F. J., Zheng, G., & Zhou, D. (2024) · Cells · doi:10.3390/cells13060528 · Cited by 40 · see citing works
The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity
Heisey, D. A. R., Lochmann, T. L., Floros, K. V., Coon, C. M., Powell, K. M., Jacob, S., Calbert, M. L., Ghotra, M. S., Stein, G. T., Maves, Y. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0277 · Cited by 35 · see citing works
Self-citationNeutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
Zoeller, J. J., Vagodny, A., Taneja, K. L., Tan, B. Y., O’Brien, N. A., Slamon, D. J., Sampath, D., Leverson, J. D., Bronson, R. T., Dillon, D. A. R., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0743 · Cited by 37 · see citing works
Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC
Potter, D. S., Galvin, M., Brown, S., Lallo, A., Hodgkinson, C. L., Blackhall, F. H., Morrow, C. J., & Dive, C. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0885 · Cited by 35 · see citing works
The chemical biology of apoptosis: Revisited after 17 years
Yang, S., Mao, Y., Zhang, H., Xu, Y., An, J., & Huang, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.019 · Cited by 35 · see citing works
Recent Advances in the Clinical Translation of Small-Cell Lung Cancer Therapeutics
Das, S., & Samaddar, S. (2025) · Cancers · doi:10.3390/cancers17020255 · Cited by 32 · see citing works
Lee, Y., Wang, L., Huang, C., Shi, Y., & Chang, L. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.019 · Cited by 31 · see citing works
Coamplification of miR-4728 protects HER2 -amplified breast cancers from targeted therapy
Floros, K. V., Lochmann, T. L., Hu, B., Monterrubio, C., Hughes, M. T., Wells, J. D., Morales, C. B., Ghotra, M. S., Costa, C., Souers, A. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717820115 · Cited by 30 · see citing works
Self-citationLu, Y., Bian, D., Zhang, X., Zhang, H., & Zhu, Z. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11686 · Cited by 30 · see citing works
Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope
Lehman, J. M., Gwin, M. E., & Massion, P. P. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0609-2 · Cited by 27 · see citing works
BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
Mukherjee, N., Strosnider, A., Vagher, B., Lambert, K. A., Slaven, S., Robinson, W. A., Amato, C. M., Couts, K. L., Bemis, J. G. T., Turner, J. A., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0932-z · Cited by 27 · see citing works
Leto, S. M., Ferri, M., Sassi, F. P., Zanella, E. R., Cottino, F., Vurchio, V., Catalano, I., Ferrero, A., Zingaretti, C. C., Marchiò, C., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2550 · Cited by 27 · see citing works
Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers
Fairlie, W. D., & Lee, E. F. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210750 · Cited by 27 · see citing works
Williams, M. M., Lee, L., Werfel, T. A., Joly, M. M., Hicks, D. J., Rahman, B., Elion, D. L., McKernan, C., Sanchez, V. M., Estrada, M. V., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0072-x · Cited by 26 · see citing works
Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers
Williams, M. M., Elion, D. L., Rahman, B., Hicks, D. J., Sanchez, V. M., & Cook, R. S. (2019) · Oncotarget · doi:10.18632/oncotarget.27070 · Cited by 26 · see citing works
Στρατικόπουλος, Η., Kiess, N., Szabolcs, M. J., Pegno, S., Cheung, K., Wu, X., Poulikakos, P. I., Cheung, P., Schmidt, H., & Parsons, R. E. (2018) · Oncogene · doi:10.1038/s41388-018-0436-4 · Cited by 25 · see citing works
Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells
Ludwig, L. M., Hawley, K. M., Banks, D. B., Thomas-Toth, A. T., Blazar, B. R., McNerney, M. E., Leverson, J. D., & LaBelle, J. L. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04285-4 · Cited by 25 · see citing works
Potter, D. S., Du, R., Bohl, S., Chow, K.-H., Ligon, K. L., Bueno, R., & Letai, A. G. (2023) · Nature Communications · doi:10.1038/s41467-023-38552-z · Cited by 24 · see citing works
HLA susceptibility genes in rheumatoid factor positive juvenile rheumatoid arthritis.
Vehe, R. K., Begovich, A. B., & Nepom, B. S. (1990) · PubMed · Cited by 24 · see citing works
Dalton, K. M., Lochmann, T. L., Floros, K. V., Calbert, M. L., Kurupi, R., Stein, G. T., McClanaghan, J., Murchie, E., Egan, R. K., Greninger, P., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009620118 · Cited by 23 · see citing works
Self-citationBritt, E., Raman, S., Leek, K., Sheehy, C. H., Kim, S. W., & Harada, H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219398 · Cited by 22 · see citing works
Self-citationBCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer
Lochmann, T. L., Bouck, Y. M., & Faber, A. C. (2018) · Oncoscience · doi:10.18632/oncoscience.455 · Cited by 22 · see citing works
Self-citationLian, B. S. X., Yek, A. E. H., Shuvas, H., Rahman, S. F. A., Muniandy, K., & Mohana‐Kumaran, N. (2018) · BMC Research Notes · doi:10.1186/s13104-018-3302-0 · Cited by 20 · see citing works
Screening and Validation of Molecular Targeted Radiosensitizers
Willers, H., Pan, X., Borgeaud, N., Korovina, I., Koi, L., Egan, R. K., Greninger, P., Rosenkranz, A., Kung, J., Liss, A. S., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.07.1694 · Cited by 21 · see citing works
Self-citationDiscovery of Mcl-1 inhibitors from integrated high throughput and virtual screening
Mady, A. S. A., Liao, C., Bajwa, N., Kump, K. J., Abulwerdi, F. A., Lev, K. L., Miao, L., Grigsby, S. M., Perdih, A., Stuckey, J. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27899-9 · Cited by 19 · see citing works
Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
Shang, E., Zhang, Y., Shu, C., Ishida, C. T., Bianchetti, E., Westhoff, M., Karpel‐Massler, G., & Siegelin, M. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-33784-2 · Cited by 19 · see citing works
Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
Zhang, Y., Ishida, C. T., Shu, C., Kleiner, G., Sanchez‐Quintero, M. J., Bianchetti, E., Quinzii, C. M., Westhoff, M., Karpel‐Massler, G., & Siegelin, M. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-25802-0 · Cited by 18 · see citing works
Ding, X., Zhang, Y., Huang, T., Xu, G., Peng, C., Chen, G., Kong, B., Frieß, H., Shen, S., Lv, Y., et al. (2019) · PubMed Central · Cited by 18 · see citing works
Wu, Z., Hu, Z., Han, X., Li, Z., Zhu, Q., Wang, Y., Zheng, Q., & Yan, J. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.087 · Cited by 18 · see citing works
NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263
Dastur, A., Choi, A., Costa, C., Yin, X., Williams, A. F., McClanaghan, J., Greenberg, M., Roderick, J. E., Patel, N. U., Boisvert, J. L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0867 · Cited by 17 · see citing works
Self-citationChiou, J., Lee, Y., Huang, C., Shi, Y., Wang, L., & Chang, L. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114857 · Cited by 17 · see citing works
Li, Y., Deutzmann, A., Choi, P. S., Fan, A. C., & Felsher, D. W. (2016) · Oncotarget · doi:10.18632/oncotarget.8731 · Cited by 16 · see citing works
Vera, M. B., Morris-Hanon, O., Nogueiras, G. I., Ripari, L. B., Esquivel, M. I., Perez-Castro, C., Romorini, L., Sevlever, G. E., Scassa, M. É., & Videla-Richardson, G. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-20910-4 · Cited by 15 · see citing works
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stress
Varkaris, A. S., Wang, K., Nouri, M., Kozlova, N. V., Schmidt, D. R., Stavridi, A.-M., Arai, S., Ambrosio, N., Poluben, L., Jiménez‐Vacas, J. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60238-x · Cited by 13 · see citing works
Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy
Hao, Z., & Veedu, J. S. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.09.003 · Cited by 13 · see citing works
Inoue‐Yamauchi, A., & Oda, H. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.03.139 · Cited by 13 · see citing works
Khawaja, H., Briggs, R., Latimer, C. H., Rassel, M., Griffin, D., Hanson, L., Bardelli, A., Di Nicolantonio, F., McDade, S. S., Scott, C. J., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0301 · Cited by 12 · see citing works
“There is a growing body of evidence suggesting that deficient apoptosis induction following targeted therapy treatments can lead to a lack of efficacy (37, 38).”
BackgroundOhgino, K., Terai, H., Yasuda, H., Nukaga, S., Hamamoto, J., Tani, T., Kuroda, A., Arai, D., Ishioka, K., Masuzawa, K., et al. (2020) · Cancer Science · doi:10.1111/cas.14569 · Cited by 11 · see citing works
Aregawi, L. G., Shokrolahi, M., Gebremeskel, T. G., & Csiki, Z. (2023) · Cureus · doi:10.7759/cureus.46061 · Cited by 12 · see citing works
McCorkle, J. R., Ahn, R., Cao, C. D., Hill, K. S., Dietrich, C. S., & Kolesar, J. (2024) · Cancers · doi:10.3390/cancers16071321 · Cited by 10 · see citing works
Rashid, M. M., Oh, H., Lee, H., & Jung, B. H. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.06.059 · Cited by 10 · see citing works
Yi, F., & Zhang, X. (2019) · Medicine · doi:10.1097/md.0000000000017253 · Cited by 9 · see citing works
- Authors
- Faber, A. C., Farago, A. F., Costa, C., Dastur, A., Gomez-Caraballo, M., Robbins, R., Wagner, B. L., Rideout, W. M., Jakubik, C. T., Ham, J., Edelman, E. J., Ebi, H., Yeo, A. T., Hata, A. N., Song, Y., Patel, N. U., March, R. J., Tam, A. T., Milano, R. J., Boisvert, J. L., Hicks, M. A., Elmiligy, S., Malstrom, S. E., Rivera, M. N., Harada, H., Windle, B. E., Ramaswamy, S., Benes, C. H., Jacks, T., & Engelman, J. A.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital Cancer Center, Boston, MA 02129;
- Koch Institute for Integrative Cancer Research At MIT (US)
- Virginia Commonwealth University (US)
- Massachusetts General Hospital (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2015-03-03
- Volume
- 112
- Issue
- 11
- Pages
- E1288-96
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4371986
- OpenAlex
- W1981797550
- Cited by
- 127
- References
- 46
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 4 · 2023: 10 · 2022: 9 · 2021: 9 · 2020: 15 · 2019: 14 · 2018: 21 · 2017: 15 · 2016: 13 · 2015: 7
- FWCI
- 8.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- HHS | NIH | National Cancer Institute (2P50 CA09057, R01CA40594, R01CA137008-01, 1U54HG006097-1, P30-CA14051)
- U.S. Department of Defense (W81-XWH-13-1-0325)
- Burroughs Wellcome Fund (n/a)
- American Cancer Society (n/a)
- Uniting Against Lung Cancer (n/a)
- Lung Cancer Research Foundation (n/a)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- navitoclax, venetoclax, BH3 mimetics, small cell lung cancer, building information modeling, Mcl-1, Bcl-2, Bcl-xL, apoptosis, combination therapy, AZD8055, rapamycin, drug resistance, cancer cell line sensitivity, patient-derived xenografts, genetically engineered mouse models
- MeSH terms
- Bcl-2-Like Protein 11, Mechanistic Target of Rapamycin Complex 1, Mechanistic Target of Rapamycin Complex 2, Aniline Compounds, Animals, Antineoplastic Combined Chemotherapy Protocols, Dose-Response Relationship, Drug, Genetic Engineering, Humans, Lung Neoplasms, Membrane Proteins, Morpholines, Proto-Oncogene Proteins, Remission Induction, Sulfonamides, Apoptosis, Inhibitory Concentration 50, Xenograft Model Antitumor Assays, Cell Line, Tumor, Multiprotein Complexes, Apoptosis Regulatory Proteins, Mice, Small Cell Lung Carcinoma, TOR Serine-Threonine Kinases, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
